难治性心力衰竭的内科治疗进展

摘要

Refractory heart failure ( RHF) is a familiar complication of cardiovascular disease in end-stage.And it is unsuccessful to treat RHF by a single medicine .Currently, the efficiency of RHF treatment was improved by combination of convenitional medicines , clinical application of milrinone , recombinant human brain natriuretic peptide and levosimendan .The application of organ support such as blood purification technology , intra-aortic balloon pump , ventricular assist device and extracorporeal membrane oxygenation was benefit to RHF therapy .Recent development of RHF treatment in internal medicine was outlined in this paper .%难治性心力衰竭（ refractory heart failure ， RHF）是终末期心血管病常见的并发症，由于病理生理机制复杂，单一药物治疗难度极大。目前，通过传统药物的联合治疗，米力农、重组人脑利钠肽（ recombinant human brain natriuretic peptide ， rh-BNP）和左西孟旦等新型药物的临床运用，血液净化、主动脉球囊反搏、心室辅助装置和体外模肺氧合等脏器支持的实施，RHF救治成功率得到提高。本文就近年来RHF内科治疗进展进行综述。